# First Light Asset Management, LLC

> Institutional holdings reported to the SEC as of Q2 2026 on Form 13F. CIK 1600004. Source: https://holderbook.com/funds/1600004-first-light-asset-management-llc/

- Reported value: $1.6B
- Positions: 31
- Weight of the ten largest: 60.7%
- Filed: 2026-08-14

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| NEOGENOMICS INC | [NEO](https://holderbook.com/stocks/NEO/) | $179.2M | 12,279,523 | 10.9% | 31 |
| SI-BONE INC | [SIBN](https://holderbook.com/stocks/SIBN/) | $132.6M | 8,127,985 | 8.1% | 29 |
| AXOGEN INC | [AXGN](https://holderbook.com/stocks/AXGN/) | $126.9M | 2,748,361 | 7.7% | 24 |
| APOGEE THERAPEUTICS INC | [APGE](https://holderbook.com/stocks/APGE/) | $123.5M | 930,289 | 7.5% | 3 |
| PALVELLA THERAPEUTICS INC NE | [PVLA](https://holderbook.com/stocks/PVLA/) | $118.0M | 771,901 | 7.2% | 4 |
| TWIST BIOSCIENCE CORP | [TWST](https://holderbook.com/stocks/TWST/) | $74.9M | 727,933 | 4.6% | 7 |
| ENLIVEN THERAPEUTICS INC | [ELVN](https://holderbook.com/stocks/ELVN/) | $69.1M | 1,360,750 | 4.2% | 2 |
| GUARDANT HEALTH INC | [GH](https://holderbook.com/stocks/GH/) | $66.3M | 441,586 | 4.0% | 15 |
| 908 DEVICES INC | [MASS](https://holderbook.com/stocks/MASS/) | $54.7M | 6,282,804 | 3.3% | 6 |
| AMYLYX PHARMACEUTICALS INC | [AMLX](https://holderbook.com/stocks/AMLX/) | $54.3M | 3,023,256 | 3.3% | 4 |
| GENEDX HOLDINGS CORP | [WGS](https://holderbook.com/stocks/WGS/) | $53.8M | 783,923 | 3.3% | 2 |
| SIMULATIONS PLUS INC | [SLP](https://holderbook.com/stocks/SLP/) | $51.1M | 2,792,677 | 3.1% | 5 |
| TANDEM DIABETES CARE INC | [TNDM](https://holderbook.com/stocks/TNDM/) | $51.1M | 3,383,553 | 3.1% | 3 |
| CRINETICS PHARMACEUTICALS IN | [CRNX](https://holderbook.com/stocks/CRNX/) | $50.9M | 1,360,866 | 3.1% | 19 |
| NEUROPACE INC | [NPCE](https://holderbook.com/stocks/NPCE/) | $45.5M | 2,861,167 | 2.8% | 6 |
| EDGEWISE THERAPEUTICS INC | [EWTX](https://holderbook.com/stocks/EWTX/) | $44.5M | 1,095,171 | 2.7% | 7 |
| ANAPTYSBIO INC | [ANAB](https://holderbook.com/stocks/ANAB/) | $39.3M | 582,004 | 2.4% | 13 |
| TREVI THERAPEUTICS INC | [TRVI](https://holderbook.com/stocks/TRVI/) | $39.1M | 2,097,215 | 2.4% | 1 |
| SEPTERNA INC | [SEPN](https://holderbook.com/stocks/SEPN/) | $32.3M | 963,260 | 2.0% | 3 |
| TRISALUS LIFE SCIENCES INC | [TLSI](https://holderbook.com/stocks/TLSI/) | $29.8M | 6,552,491 | 1.8% | 2 |
| TECTONIC THERAPEUTIC INC | [TECX](https://holderbook.com/stocks/TECX/) | $27.5M | 800,726 | 1.7% | 2 |
| HEALTH CATALYST INC | [HCAT](https://holderbook.com/stocks/HCAT/) | $25.5M | 12,810,861 | 1.5% | 28 |
| BUTTERFLY NETWORK INC | [BFLY](https://holderbook.com/stocks/BFLY/) | $22.2M | 2,642,404 | 1.4% | 7 |
| ESTABLISHMENT LABS HLDGS INC | [ESTA](https://holderbook.com/stocks/ESTA/) | $21.2M | 246,577 | 1.3% | 6 |
| VAXCYTE INC | [PCVX](https://holderbook.com/stocks/PCVX/) | $20.1M | 345,157 | 1.2% | 2 |
| IRHYTHM HOLDINGS INC | [IRTC](https://holderbook.com/stocks/IRTC/) | $19.9M | 167,092 | 1.2% | 7 |
| OMNICELL COM | [OMCL](https://holderbook.com/stocks/OMCL/) | $18.8M | 452,324 | 1.1% | 2 |
| ATRICURE INC | [ATRC](https://holderbook.com/stocks/ATRC/) | $15.9M | 567,838 | 1.0% | 31 |
| KORU MEDICAL SYSTEMS INC | [KRMD](https://holderbook.com/stocks/KRMD/) | $14.2M | 3,387,902 | 0.9% | 31 |
| TACTILE SYS TECHNOLOGY INC | [TCMD](https://holderbook.com/stocks/TCMD/) | $13.8M | 462,562 | 0.8% | 1 |
| RHYTHM PHARMACEUTICALS INC | [RYTM](https://holderbook.com/stocks/RYTM/) | $9.5M | 85,765 | 0.6% | 4 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q2 2026 | +35.5% | +14.8% | +20.6% | 94% |
| Q1 2026 | -10.3% | -4.6% | -5.7% | 100% |
| Q4 2025 | +29.2% | +2.4% | +26.8% | 91% |
| Q3 2025 | +22.3% | +7.8% | +14.5% | 100% |
| Q2 2025 | -2.8% | +10.5% | -13.3% | 99% |
| Q1 2025 | -11.6% | -4.6% | -7.1% | 100% |
| Q4 2024 | -7.3% | +2.1% | -9.5% | 100% |
| Q3 2024 | +14.0% | +5.4% | +8.6% | 100% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q2 2026 | $1.6B | 31 |
| Q1 2026 | $1.1B | 35 |
| Q4 2025 | $1.3B | 33 |
| Q3 2025 | $1.1B | 41 |
| Q2 2025 | $771.3M | 38 |
| Q1 2025 | $875.7M | 37 |
| Q4 2024 | $1.0B | 36 |
| Q3 2024 | $1.2B | 38 |
| Q2 2024 | $1.1B | 44 |
| Q1 2024 | $1.3B | 50 |
| Q4 2023 | $1.2B | 75 |
| Q3 2023 | $1.1B | 75 |